You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RECIST: Response Evaluation Criteria in Solid Tumors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Protein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Tumors Trial in Guangzhou (JYP0322)

Recruiting
  • Protein Kinase Inhibitors
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Nov 9, 2023

Solid Tumor Trial (LM103)

Not yet recruiting
  • Solid Tumor
  • LM103
  • (no location specified)
Jul 25, 2023

Solid Tumor Trial (LM103)

Not yet recruiting
  • Solid Tumor
  • LM103
  • (no location specified)
Jul 25, 2023

Solid Tumor Trial in Tianjin (LM103)

Recruiting
  • Solid Tumor
  • LM103
  • Tianjin, China
    Tianjin Beichen Hospital
Jul 4, 2023

Advanced Solid Tumor Trial in San Francisco (Hyperpolarized 13C-Pyruvate, Magnetic Resonance Imaging (MRI))

Recruiting
  • Advanced Solid Tumor
  • Hyperpolarized 13C-Pyruvate
  • Magnetic Resonance Imaging (MRI)
  • San Francisco, California
    University of California, San Francisco
Dec 16, 2022

Metastatic or Locally Advanced Unresectable Solid Tumors Trial in Canada, Spain, United States (M1774, Drug A (DNA Damage

Recruiting
  • Metastatic or Locally Advanced Unresectable Solid Tumors
  • Houston, Texas
  • +4 more
Jul 7, 2022

Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1

Completed
  • Poorly Differentiated Malignant Neuroendocrine Carcinoma
  • +4 more
  • Everolimus (Afinitor®)
  • Berlin, Germany
    Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatolog
Oct 27, 2020

Biomarkers for Prediction of Tumor Response to Radiotherapy

Recruiting
  • Solid Tumors
    • Shantou, Guangdong, China
      Cancer Hospital, Shantou University Medical College
    Dec 27, 2021

    Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (biological, procedure, drug)

    Not yet recruiting
    • Advanced Malignant Solid Neoplasm
    • Refractory Malignant Solid Neoplasm
    • Atezolizumab
    • +5 more
    • (no location specified)
    Feb 4, 2023

    Advanced Solid Tumors Trial in Japan, United Kingdom, United States (BAY2965501)

    Recruiting
    • Advanced Solid Tumors
    • Denver, Colorado
    • +5 more
    Jan 19, 2023

    Advanced Solid Tumors, NSCLC Trial in Israel, United States (BAY2862789)

    Not yet recruiting
    • Advanced Solid Tumors
    • Non-small Cell Lung Cancer
    • Detroit, Michigan
    • +5 more
    May 5, 2023

    Relapsed/Refractory Small Cell Lung Cancer Trial in Worldwide (Tarlatamab)

    Recruiting
    • Relapsed/Refractory Small Cell Lung Cancer
    • Birmingham, Alabama
    • +78 more
    Jan 18, 2023

    Solid Tumor, Adult, Solid Tumor, Childhood, Hematologic Cancer Trial in Villejuif (Tumor biopsy, Blood sample, Bone marrow

    Recruiting
    • Solid Tumor, Adult
    • +2 more
    • Tumor biopsy
    • +2 more
    • Villejuif, Val De Marne, France
      Gustave Roussy Cancer Campus Grand Paris
    Jul 28, 2022

    Malignant Tumor Trial (Experimental: DaRT seeds)

    Not yet recruiting
    • Malignant Tumor
    • Experimental: DaRT seeds
    • (no location specified)
    Mar 27, 2023

    Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)

    Not yet recruiting
    • Solid Tumor
    • +2 more
    • favezelimab/pembrolizumab
    • +2 more
    • (no location specified)
    Sep 7, 2023

    Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation Trial in Baltimore (Recommendation for treatment with

    Recruiting
    • Metastatic Solid Tumor
    • +4 more
    • Recommendation for treatment with immunotherapy
    • Baltimore, Maryland
      Johns Hopkins University
    Sep 8, 2022

    Cancer Trial in New Orleans, Allentown

    Recruiting
    • Cancer
      • New Orleans, Louisiana
      • +1 more
      Oct 14, 2022

      Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT Benefit Trial in Stanford, Portland ([18F]F-AraG)

      Not yet recruiting
      • Solid Tumor
      • Fluorine F 18 Ara-G
      • Palo Alto, California
        Stanford University
      Feb 1, 2022

      Squamous Cell Carcinoma Trial (MK-3475A)

      Not yet recruiting
      • Squamous Cell Carcinoma
      • MK-3475A
      • (no location specified)
      Sep 11, 2023

      Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

      Active, not recruiting
      • Neoplasm
      • Beijing, China
      • +5 more
      Jan 31, 2023

      Circulating Tumor DNA for Early Treatment Response Assessment of

      Recruiting
      • Healthy Volunteer
      • +12 more
        • Saint Louis, Missouri
          Washington University School of Medicine
        Apr 4, 2022

        Prostate Cancer Metastatic Trial (MK-5684, Abiraterone acetate, Enzalutamide)

        Not yet recruiting
        • Prostate Cancer Metastatic
        • (no location specified)
        Nov 21, 2023

        Hepatocellular Carcinoma Trial in Worldwide (lenvatinib, pembrolizumab (200 mg))

        Completed
        Has Results
        • Hepatocellular Carcinoma
        • San Francisco, California
        • +25 more
        Jan 13, 2023

        Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

        Recruiting
        • Advanced Solid Tumors
        • Metastatic Solid Tumors
        • Lyon, France
          Centre Léon Bérard
        Nov 30, 2022

        ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

        Active, not recruiting
        Has Results
        • ALK-positive Advanced NSCLC
        • Orange, California
        • +79 more
        Nov 15, 2022